Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease...

Area of Science:

• Neuroimmunology
• Cellular Biology
• Pathology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune CNS disorder causing demyelination, axonal injury, and neurological deficits.
• Current MS therapies primarily use immunosuppression, lacking specific treatments for cell death-induced injury.
• MS pathogenesis involves an auto-amplifying cycle of inflammation and cell death.

Purpose of the Study:

• To investigate the role of ferroptosis, an iron-catalyzed regulated cell death (RCD), in multiple sclerosis (MS) pathogenesis.
• To evaluate the therapeutic potential of targeting ferroptosis in preclinical MS models.

Main Methods:

• Analysis of active and chronic MS lesions and cerebrospinal fluid (CSF) for ferroptosis markers.
• Assessment of iron levels, peroxidized phospholipids, and lipid degradation products in MS patient samples.
• Evaluation of a ferroptosis inhibitor (UAMC-3203) in a preclinical model of relapsing-remitting MS.

Main Results:

• Evidence of ferroptosis, including elevated iron, peroxidized phospholipids, and lipid degradation products, was found in MS lesions and CSF.
• Treatment with the ferroptosis inhibitor UAMC-3203 significantly delayed relapse and ameliorated disease progression in a preclinical MS model.

Conclusions:

• Ferroptosis is identified as a detrimental and targetable factor contributing to MS disease progression.
• Targeting ferroptosis represents a novel therapeutic strategy for MS, potentially complementing existing immunosuppressive treatments.